42a74ac9 E32a 4b9a 800f 1d3d5fdfc000 01
Chemical structure of capecitabine, shown as a molecular diagram with detailed bonding and atom arrangement.*
Capecitabine Tablet, Film Coated
Product Images NDC 69097-949
9 FDA label images from Cipla Usa Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 69097-949). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
42a74ac9 E32a 4b9a 800f 1d3d5fdfc000 02
An enzymatic conversion diagram illustrating the metabolic pathway of Capecitabine. It shows Capecitabine being converted to 5'-DFCR by carboxylesterase, then to 5'-DFUR by cytidine deaminase, and finally to 5-FU by dThdPase enzymes.*
42a74ac9 E32a 4b9a 800f 1d3d5fdfc000 03
A survival curve graph comparing treatment groups 5-FU + Leucovorin and Capecitabine over time in months since randomization. The solid line represents Capecitabine, and the dashed line represents 5-FU + Leucovorin. The x-axis shows months since randomization, and the y-axis represents survival probability, with risk numbers listed below the x-axis.*
42a74ac9 E32a 4b9a 800f 1d3d5fdfc000 04
A Kaplan-Meier survival curve comparing two treatment groups: 5-FU + Leucovorin (dashed line) and Capecitabine (solid line). The x-axis represents months since randomization from 0 to 96, and the y-axis represents survival probability from 0.0 to 1.0. The number of patients at risk is listed below the x-axis for each time point.*
42a74ac9 E32a 4b9a 800f 1d3d5fdfc000 05
A survival probability chart comparing two treatment groups over time in days. The chart shows estimated probability on the y-axis against time on the x-axis. One group is treated with 5-FU plus Leucovorin (Mayo Regimen) represented by a dashed line, and the other with Capecitabine 1,250 mg/sqm twice daily (intermittent) represented by a solid line. The plot shows survival trends for both groups up to approximately 1,200 days, with specific probability values highlighted around 300 days.*
42a74ac9 E32a 4b9a 800f 1d3d5fdfc000 06
A Kaplan-Meier survival curve chart depicting estimated probability over time (days) for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1,250 mg/sqm twice daily intermittent with Docetaxel 75 mg/sqm every 3 weeks (solid line). The x-axis represents time in days, ranging from 0 to 800, and the y-axis represents estimated probability from 0.0 to 1.0.*
42a74ac9 E32a 4b9a 800f 1d3d5fdfc000 07
A survival curve graph depicting estimated probability over time (days) for two groups: one receiving Docetaxel 100 mg/sqm every 3 weeks (dashed line) and the other receiving Capecitabine 1,250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks (solid line). The graph shows probability decreasing over approximately 800 days, with vertical markers around days 352 and 442.*
42a74ac9 E32a 4b9a 800f 1d3d5fdfc000 08
Capecitabine 150 mg film-coated tablets label from Cipla USA Inc. The packaging indicates 60 tablets per container with instructions to dispense an accompanying patient information leaflet. Storage instructions specify 25°C (77°F) with permitted excursions, and the label includes manufacturer details from MSN Laboratories Private Limited, India, and distributor information for Cipla USA Inc., Florida. The label also features a barcode and a designated area for variable data coding.*
42a74ac9 E32a 4b9a 800f 1d3d5fdfc000 09
Capecitabine Tablets, USP 500 mg film-coated tablets label showing 120 tablets per container. The label includes storage instructions, pharmacist dispensing advice, manufacturer MSN Laboratories Private Limited (India), and distributor Cipla USA Inc. The NDC is 69097-948-08 with barcode present.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
